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I. Summary
MULLERIAN inhibiting substance (MIS) is the gonadalhormone that causes regression of the Mullerian
ducts, the anlagen of the female internal reproductive struc-
tures, during male embryogenesis. MIS is a member of the
large transforming growth factor-/? (TGF/3) multigene family
of glycoproteins that are involved in the regulation of growth
and differentiation. The proteins in this gene family are all
produced as dimeric precursors and undergo posttransla-
tional processing for activation, requiring cleavage and dis-
sociation to release bioactive C-terminal fragments. Similarly,
the 140 kilodalton (kDa) disulfide-linked homodimer of MIS
is proteolytically cleaved to generate its active C-terminal
fragments. The sexually dimorphic expression of MIS in
Sertoli cells of the testis and granulosa cells of the ovary is
critical for normal differentiation of the internal reproductive
tract structures. A number of extra-Mullerian functions such
as control of germ cell maturation and gonadal morphoge-
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nesis, induction of the abdominal phase of testicular descent,
suppression of lung maturation, and growth inhibition of
transformed cells have also been proposed for this growth-
inhibitory hormone and will be discussed. This article will
summarize the current understanding of the biology and
multiple functions of MIS including its activation, regulation,
and mechanism of action and discuss areas of interest in
ongoing research.
II. Introduction
Professor Alfred Jost first proposed that a testicular factor
distinct from testosterone causes regression of the Mullerian
ducts during male embryonic development (1). This hor-
mone, termed Mullerian Inhibiting Substance (MIS), was
subsequently identified as a growth-inhibitory glycoprotein
related to the TGFjSs, inhibins, and activins (2). In the 50 yr
since the "Mullerian inhibitor" was first postulated, MIS, also
known as anti-Mullerian hormone (3), has been purified,
cloned, and recombinantly produced (4-7), and a recently
isolated candidate receptor gene is being characterized. Much
has been learned about its regulation and mechanism of
action (2, 5, 8-10), including evidence that MIS is tightly
regulated in the SRY switch for sexual dimorphism, and that
both primary and secondary cleavages are required for acti-
vation (11, 12). These new findings will affect the biological
functions of MIS and the molecular mechanisms by which
MIS exerts its effects on cell cycle kinetics and cellular
differentiation.
Early in mammalian fetal development, the gonads are
bipotential and both Mullerian and Wolffian ducts are pres-
ent in the urogenital ridge: the former are the anlagen of the
uterus, Fallopian tubes, and upper third of the vagina, and
the latter are the embryologic precursors of the epididymis,
vas deferens, and seminal vesicles (1, 13). The Mullerian
ducts of both male and female embryos are transiently
responsive to MIS during development, then lose their sen-
sitivity after this critical period (3,13). During embryogenesis
in males, MIS causes involution of the Mullerian ducts while
testosterone stimulates differentiation of the Wolffian ducts,
whereas in females the Mullerian ducts differentiate spon-
taneously in the absence of MIS, while the Wolffian ducts
involute in the absence of testosterone. MIS continues to be
produced by Sertoli cells even after regression of the Muller-
ian ducts is complete; expression in the testes remains high
after birth, then decreases markedly thereafter to the low
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levels found at puberty (14-17). Furthermore, ovarian pro-
duction of MIS starts postnatally and is highest in the pu-
bertal and adult ovary (15, 18-20). The secretion of MIS by
the ovary, and by the testis after Mullerian duct regression
is complete, is suggestive of additional extra-Mullerian bio-
logical functions for MIS. Other potential roles for this unique
growth-inhibitory hormone include control of germ cell and
gonadal differentiation (21, 22), induction of the abdominal
phase of testicular descent (8, 23, 24), suppression of lung
maturation (25, 26), and growth inhibition of transformed
cells (4, 27-30). We will summarize the current understand-
ing of the biology of MIS, including its regulation, mechanism
of action, and recently elucidated extra-Mullerian functions.
We will also review the clinical applications for measurement
of serum MIS. Much of the material that has been discussed
previously will not be presented in detail.
III. Biology of MIS
A. Protein and gene structure
MIS is a member of a large multigene family of glycopro-
teins involved in the regulation of growth and differentiation
(31, 32). The proteins in this gene family, the TGF/3s (33),
inhibin (34), activins (35, 36), Xenopus Vg-1 (37), Drosophila
decapentaplegia complex (38), and bone morphogenesis fac-
tors (39), have C-terminal homology, particularly around
seven highly conserved cysteine residues (31). Many of these
proteins are produced as dimeric precursors that undergo
similar posttranslational processing for activation, requiring
cleavage and dissociation to release disulfide-linked bioactive
C-terminal fragments (12, 29, 31).
The highly conserved MIS proteins are synthesized as 553
(rat) to 575 (bovine) amino acid precursors, with short amino
acid leader sequences consisting of a signal peptide and a
putative pro-sequence predicted by von Heijne analysis (Fig.
1) (40). Across species, MIS has 11 to 12 conserved cysteines,
of which seven are in the C-terminal domain. The C-termi-
nus has the strongest homology, with 108 of the last 112
amino acids conserved between the bovine and human pro-
tein, and 104 of 112 amino acids conserved between the rat
and human protein. The least conserved amino acids in the
C-terminus are the ones surrounding the primary cleavage
site.
Genomic and/or complementary DNA clones have been
isolated for human (41), bovine (41), rat (42), and mouse (43)
MIS. The MIS genes have similar intron/exon structures with
a high GC content of 72% in the five exons and 68% in the
introns and flanking regions. The bovine, human, and rat
genes have 65-80% nucleotide homology across the coding
regions and 70-75% homology in the promoter regions. The
5'-untranslated regions contain only 10 (bovine and human)
or 8 (mouse and rat) nucleotides, and therefore are unlikely
to exert translational control, but could function as transcrip-
tional regulatory elements. The 3'-untranslated regions of
MIS are also relatively short, from 62 nucleotides in the rat
to 112 in humans. The human MIS gene has been mapped
to chromosome 19, pl3.2-13.3 (44) and the mouse MIS gene
to chromosome 10 (45).
Recent studies indicate that rat MIS has two develop-
mentally regulated messenger RNA transcripts that are dif-
ferentially polyadenylated (46). A larger 2.0 kilobase species
is abundant by day 14 in embryonic testes, then decreases
markedly at birth, and is barely detectable postnatally. A
smaller 1.8 kilobase species is detectable at embryonic day
18, and prominent at day 21, then decreases markedly, but
remains detectable postnatally. Although the biological sig-
nificance of the two transcripts is not known, the differential
polyadenylation may affect the stability or translatability of
the two mRNAs as described for other systems (47).
B. Processing and activation
The early methods of purification of MIS from bovine
testes by sequential diethylaminoethyl ion exchange, dye-
affinity, or immunoaffinity chromatography yielded partially
purified preparations of MIS that remain biologically active
in the organ culture assay as well as in the antiproliferative
assays (48). Currently MIS is recombinantly produced in
Chinese hamster ovary (CHO) cells transfected with the
human MIS gene driven by the SV40 early promoter (4, 41).
Recombinant human MIS (rhMIS) is highly purified from
conditioned media by immunoaffinity chromatography using
a mouse monoclonal antibody to MIS (7, 49). Elution of
immunoaffinity-purified rhMIS with either 1 M acetic acid or
2 M NaSCN yields MIS preparations that are 90-95% purified
and active in the bioassay but with variable activity in the
antiproliferative assays (49). Addition of a salt wash step
with 0.5 M sodium chloride before the acid elution, however,
results in the removal of a low molecular weight triplet that
has growth-promoting effects (11). These proteins are not
recognized by MIS antibodies and are also present in media
from wild-type CHO cells. MIS purified after this pre-elution
salt wash retains both antiproliferative activity and Mullerian
duct regression bioactivity (27, 30).
Mature MIS undergoes glycosylation and dimerization and
is secreted as a 140 kilodalton (kDa) dimer of two identical
disulfide-linked subunits (2, 9, 50). Two presumptive re-
linked glycosylation sites are found in the N-terminal portion
of the molecule (Fig. 1), one of which is not conserved in the
rat. Their role in the processing or mechanism of action of
MIS remains to be determined as removal of N-linked com-
plex carbohydrates with endoglycosidase F does not result in
loss of bioactivity (2). On reducing sodium dodecyl sulfate-
polyacrylamide gels, MIS has an electrophoretic pattern con-
sisting of a major doublet at 70 kDa and primary cleavage
products at 57 and 12.5 kDa (11, 12). Plasmin treatment
results in more complete cleavage of MIS to its 57 kDa N-
terminal and 12.5 kDa C-terminal fragments. Amino acid
sequence analysis indicates that MIS is cleaved between Arg
427 and Ser 428 near its C terminus (Fig. 1), at a position
similar to the cleavage sites of other members of this gene
family. The amino acids surrounding the MIS Arg-Ser site,
however, resemble a monobasic consensus cleavage site (51)
rather than the dibasic or tetrabasic site present in the TGF/3
gene family (31). When plasmin-treated preparations of MIS
are immunoaffinity-purified with a monoclonal antibody
specific for the N terminus, the C-terminal dimer co-purifies
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Pre-Pro Sequence
FIG. 1. Primary amino acid sequence of
human MIS. A 24 amino acid leader
(pre-pro) sequence is cleaved to generate
the 536 amino acid mature protein,
which then undergoes proteolytic proc-
essing for activation. Primary cleavage
of human MIS at arginine 427 (arrow)
yields the predominant 57.5 kDa N- and
12.5 kDa C-terminal fragments. Second-
ary cleavage of MIS occurs at arginine
229 (arrow) of the N-terminal moiety to
yield 34 and 22 kDa fragments. The two
N-linked glycosylation sites (double ar-
rowheads), the leucine repeats suround-
ing the primary cleavage site (black
boxes), and the seven cysteines that are
conserved in the TGF/3 family (open cir-
cles) are delineated.
MRDLPLTSLALVLSALGALLGTEALRAEEPAVGTSGLIFREDLDWPPGIPQEP
LCLVALGGDSNGSSSPLRVVGALSAYEQAFLGAVQRARWGPRDLATFGVCN
TGDRQAALPSLRRLGAWLRDPGGQRLVVLHLEEVTWEPTPSLRFQEPPPGGA
GPPELALLVLYPGPGPEVTVTRAGLPGAQSLCPSRDTRYLVLAVDRPAGAWR
I
GSGLALTLQPRGEDSRLSTARLQALLFGDDHRCFTRMTPALLLLPR'SEPAPL
229
PAHGQLDTVPFPPPRPSAELEESPPSADPFLETLTRLVRALRVPPARASAPR
LALDPDALAGFPQGLVNLSDPAALERLLOGEEPLLLLLRPTAATTGDPGGPG
• • • • • •
PAPLHDPTSAPWATALARRVAAELQAAAAELRSLPGLPPATAPLLARLLAL
• • • X o •
CGLGDPLR ALLLLKALQGLRVEWRGRDPRGPGRAQR SAG ATAADGPCALR
4 2 7
• • 0 0
ELSVDLRAERSVMPETYQANNCQGVCGWPQSDRNPRYGNHVVLLLKMQA
00 0 0
RGAALARPPCCVPTAYAGKLLISLSEERISAHHVPNMVATECGCR
leucine repeats o conserved cysteines glycosylation sites I cleavage sites
with the N-terminal dimer, indicating that the fragments
remain in noncovalent association (2, 29). The cleaved di-
meric complex remains active in the bioassay when disso-
ciated with 1 % sodium deoxycholate, but unlike the TGF/3s,
loses activity when dissociated with prolonged acidification
or boiling (12). When Arg 427 at the primary cleavage site is
converted to threonine by site-directed mutagenesis, the
mutated MIS is noncleavable and inactive in the organ
culture assay, confirming that proteolytic processing of MIS
is obligatory for full bioactivity (2, 12). Prolonged exposure
of MIS to plasmin results in further proteolysis of the 57 kDa
N-terminal moiety, generating 34 and 22 kDa fragments (11).
By amino acid sequence analysis, this secondary cleavage
site is probably at Arg 229-Ser 230.
The N- and C-terminal cleavage products of holo-MIS
have been separated and isolated by column chromatogra-
phy after plasmin cleavage of holo-MIS and tested for activ-
ity individually in the various assays (29, 51a). The 25 kDa
C-terminal dimers are consistently active in the organ culture
assay, whereas the 110 kDa N-terminal dimers are inactive.
The bioactivity of the C-terminal fragment is not enhanced
by the addition of N-terminal dimers in our quantitative bio-
assay (29) although rapid aggregation of the isolated frag-
ments makes it difficult to assess their stoichiometric roles in
MIS action. In a nonquantitative organ culture assay, the
N-terminal domain appears to potentiate the effects of the
C-terminus (51a). When tested in an antiproliferative assay,
the C-terminal fragments inhibit proliferation of A-431 cells
while the solubilized N-terminal fragments isolated from the
same starting material fail to suppress growth at equimolar
concentrations (29). Again N- and C-terminal fragments
added together did not have enhanced activity. The C-
terminal fragment is also the active moiety in a bioassay that
measures the ability of MIS to suppress aromatase activity in
cultured rat ovaries although addition of either N-terminal
fragments or FCS enhances the effect (51a). These data
confirm that the Mullerian duct regression bioactivity and
antiproliferative activity of MIS reside primarily in its C-
terminal domain. The variable activity of holo-MIS prepa-
rations in the different assays may be attributable to an
endogenous protease present in some of the systems, such
as the organ culture assay, but not in others.
C. Mechanism of action
Although the molecular mechanism of action of MIS has
not been fully elucidated, it is thought to involve receptor-
mediated dephosphorylation (10, 52). A potential interaction
between MIS and epidermal growth factor (EGF) was inves-
tigated after similarities were noted between MIS and a
membrane-bound phosphotyrosyl protein phosphatase that
reverses EGF-stimulated phosphorylation (53). This phos-
phatase is activated by EDTA and fluoride and inhibited by
zinc and vanadate. Similarly fluoride and EDTA mimic, and
zinc and vanadate antagonize, the effects of MIS on the
Mullerian duct (52, 54). EGF, with 1 HIM manganese as a
cofactor, was therefore tested in the organ culture assay and
found to inhibit MIS-stimulated ductal regression. Nerve
growth factor and fibroblast growth factor as well as other
mitogens with receptor tyrosine kinase activity, such as in-
sulin and platelet-derived growth factor, did not affect MIS
activity, indicating that the interaction between MIS and EGF
is specific (5, 52). Bovine MIS was later found to inhibit
colony formation of an EGF receptor-rich vulvar carcinoma
cell line (A-431) that requires EGF for growth in soft agar
(55, 56). Bovine MIS inhibits EGF- induced membrane tyro-
sine phosphorylation in this cell line without competing for
EGF receptor binding sites or diminishing the phosphoryla-
tion of prelabeled EGF receptors. MIS and EGF also have
opposing effects on EGF receptor autophosphorylation in
fetal rat lung fibroblasts (57) and on germinal vesicle break-
down in the oocyte, which is inhibited by MIS and stimulated
by EGF (58). Thus EGF and MIS have opposing effects on
cellular growth and differentiation in a number of systems.
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Another example of a growth inhibitor that antagonizes
growth factor-stimulated tyrosine phosphorylation is the 63
kDa phosphoprotein, derived from conditioned media of
liver tumor cells, that has partial sequence homology to MIS
(59). This phosphoprotein inhibits the growth and insulin-
stimulated insulin receptor autophosphorylation of liver cells.
A clue to the mechanism of action for MIS was suggested
by the recent cloning and identification of activin (60) and
TGF/3 type II receptors (61) as serine-threonine kinases. The
MIS receptor is likely to be a member of this same receptor
family and may have similar functional properties (W. W.
He, M. L. Gustafson, and P. K. Donahoe, unpublished data).
Complete characterization of the MIS receptor will permit a
fuller understanding of the molecular action of MIS and will
help to delineate the molecular basis for the opposing actions
of MIS and EGF.
D. Hormonal regulation
The hormonal regulation of MIS has been examined in
both animal models and tissue culture systems. Testes from
neonatal Sprague-Dawley rats treated with LHRH antiserum
in utero had greater MIS bioactivity than testes from vehicle-
treated rats (62). Treatment of the newborn pups with FSH
for 5 days after birth reversed this effect, while human CG
(hCG) had no effect, indicating that the hypothalamic-pitui-
tary-gonadal axis via FSH has a role in the regulation of MIS
(63). More recent observations confirm the role of FSH in
the regulation of MIS. After twice daily injection of newborn
rats with either gonadotropins or vehicle, the testes of FSH-
treated animals had less MIS mRNA and immunoreactive
protein than those of LH- or vehicle-treated animals (Fig. 2)
(17). By the 5th postnatal day, MIS immunoreactivity had
Birth 1 day
Injection 4 4
FIG. 2. FSH regulation of MIS expres-
sion. Newborn rats injected with FSH
twice a day for 2 to 4 days have decreased
immunoreactivity of MIS in the seminif-
erous tubules of the testes compared to
vehicle-injected controls. The bar graph
depicts the staining intensity in the sem-
iniferous tubules of FSH- treated ani-
mals (shaded bars) compared to controls
(open bars), as quantitated by comput-
erized image analysis of intratubular
staining minus interstitial background
staining. [Reprinted with permission
from Kuroda et al: Endocrinology
127:1825-1832, 1990 (17). © The Endo-
crine Society.]
VEHICLE
FSH
TREATED
TESTES ,
decreased to low constitutive levels in the controls that were
indistinguishable from FSH-treated animals. Similar results
were obtained in embryos harvested at day 21, 2 days after
in utero injection on day 19 with gonadotropins or vehicle
(64). These data confirm the inhibition of MIS by FSH and
show that this modulation is transcriptionally mediated.
The latter study also examined the effects of gonadotropins
and sex steroids on MIS expression by immunohistochemical
staining with antibodies specific for the N- and C-terminal
fragments as well as holo-MIS (64). Paradoxically, the testes
of testosterone and hCG-treated fetuses had unchanged or
slightly decreased immunostaining for holo-MIS, but in-
creased staining with the N- and C-terminal antibodies. No
differences were noted in mRNA levels. Consequently, we
hypothesize that testosterone and hCG/LH, in contrast to
FSH, regulate MIS posttranslationally by enhancing the proc-
essing of holo-MIS to its N- and C-terminal fragments.
Several attempts to study the effects of FSH on cultured
cells have been hindered by the progressive decline in the
synthesis of MIS in primary cultures of Sertoli cells (65, 66).
An increase in cAMP concentrations in the culture media of
Sertoli cells and testicular tissue fragments after FSH treat-
ment could be demonstrated, but MIS mRNA and protein
concentrations in the media after treatment fell rapidly,
regardless of the added constituents (66). In contrast to the
down-regulation of MIS by FSH in neonatal rats, hCG and
FSH had no effect on MIS mRNA levels in cultured human
fetal Sertoli cells whereas (Bu)2cAMP induces MIS mRNA 5-
fold (67). In cultures of adult human granulosa cells collected
after hormonal stimulation for in vitro fertilization, MIS
mRNA levels were induced 9-fold by (Bu)2cAMP and 5-fold
by hCG, but FSH, insulin, and progesterone had no effect
2 day 3 day 4 day
INTRATUBULAR
DENSITY
DIFFERENCE
46%
29%
6 1 %
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(67). Further studies of MIS regulation in vitro will be facili-
tated by the availability of cell lines that express MIS. These
are currently being developed in our laboratory by manipu-
lating culture conditions for Sertoli cells and by retroviral
transfection of primary cultures and established cell lines.
E. Gene regulation
Identification and characterization of the trans-acting fac-
tors and ris-acting elements responsible for the tissue-specific
and developmentally regulated expression of MIS are areas
of active research interest. The promoters of the human,
bovine, and rat genes are 75% homologous. Analysis of the
5'-flanking sequences of the human and rat genes reveals
sequences that are similar but not identical to known regu-
latory elements (42, 68). No functional role in MIS gene
regulation, however, has been demonstrated thus far for any
of these consensus regulatory sequences. A sequence with
one mismatch for the cAMP-responsive element is present
at —262 in the human but not the bovine or rat promoter
region, although MIS expression is modulated by cAMP
and FSH in the testes (17, 64, 67) and by cAMP and LH in the
ovary (67). The rat gene has a sequence at —301,
5'TCAATTAAAC3', that resembles the consensus binding
site (5'TCAATTAAAT3') for homeobox proteins such as
fushi tarazu in the Drosophila ultrabithorax promoter. The
significance of the canonical SP1 recognition sites (CCGCCC)
found in the bovine and human MIS genes is unclear because
of the high GC content in the MIS promoter. A 13 basepair
sequence (5'GGTCACAGGGACC3') that differs by one
nucleotide from the estrogen response element
(5'GGTCACAGTGACC3') of the vitellogenin gene is found
at position —1772 in the human gene. Co-transfection of the
estrogen receptor and this "ERE" inverted repeat as a 35
basepair oligonucleotide linked to a reporter gene confers
estrogen responsiveness on a heterologous promoter (68).
Nevertheless, the function of this element in vivo is unclear
as similar experiments with an 182 basepair fragment of the
MIS promoter encompassing the "ERE" and its flanking se-
quences fail to show estrogen inducibility (68).
Comparison of the rat, bovine, and human MIS genes
reveals a number of other conserved sequences with no
obvious similarities to known regulatory elements. Some of
these repeated sequences contain regions of dyad symmetry
and are postulated to have a role in the transcriptional
regulation of MIS. Mobility shift assays using oligonucleo-
tides (30-40 mers) containing these consensus regulatory
elements exhibit numerous protein-DNA interactions (C.
Haqq and P. K. Donahoe, unpublished data). One repeated
motif, 5'GGAGATAGG3', called Ml, is conserved be-
tween rat, bovine, and human MIS and is similar to the
repeated androgen-binding protein enhancer sequence,
5'GGAGAA3'. Although Ml binding exhibits the correct
developmental pattern for MIS enhancer activity, it is not
limited to testicular nuclear extracts. Thus, Ml does not
confer tissue-specific expression but may be critical for basal
MIS expression or may act in conjunction with other cis-
acting elements to direct tissue- or age-specific expression.
Another putative binding site, termed M2 (M2-5' and
M2-3'), is found at -102 to -78 in the rat gene. M2-5' is
a unique sequence with dyad symmetry (5'-
GCCAGGCACTGTC3'). M2-3' (5'CCCAAGGTCA3') is re-
peated at —200 with one mismatch and again seven times
between -600 to -900. Mobility shift assays with M2 oli-
gonucleotides show tissue- and sex-specific protein-DNA
binding that is consistent with MIS expression in vivo except
for low levels in nuclear extracts from the newborn male
brain. Ovarian M2 binding proteins are lower in molecular
weight than testicular proteins and have a different devel-
opmental pattern of expression.
The initial activation of MIS transcription during embry-
ogenesis may be part of a hierarchal cascade of transcrip-
tional events that regulate sexually dimorphic development.
Because MIS is one of the earliest sexually dimorphic genes
expressed during development, SRY, the putative testis de-
termining gene, may be involved in initiating its transcrip-
tion. In the mouse, Sry is expressed from days 10.5 to 12.5
postcoitus, when the undifferentiated gonad is forming ag-
gregates of pre-Sertoli cells surrounding the germ cells (69).
MIS expression is first detected at day 12.5 postcoitus in the
mouse (43) and at the developmentally equivalent day 13.5
in the rat (70). The sequential timing of SRY and MIS
expression is consistent with activation of MIS by SRY. The
DNA binding domain of SRY has a conserved sequence
motif shared by high mobility group transcription factors.
This 80 amino acid domain, purified as a cleavable glutathi-
one transferase chimeric protein, recognizes an upstream
element (designated SRYe) in the promoter region of the MIS
gene with nanomolar affinity and with tissue and develop-
mental specificity (70a). Competitive binding experiments
with the mutated binding element confirm the specificity of
the binding. These results support the hypothesis that SRY
and MIS are sequential elements in a genetic program that
controls sexual dimorphism.
F. Receptor characterization
Characterization of the MIS receptor has been a challeng-
ing task. Although the complex mesenchymal and epithelial
interactions observed during Mullerian duct regression (71)
make it difficult to determine if MIS receptors are present
in both epithelial and mesenchymal cells of the Mullerian
duct, recent work indicates that MIS acts directly on mesen-
chymal cells and indirectly through the mesenchyme on
epithelial cells (72). Consequently, the mesenchymal cells of
the urogenital ridge may be the primary source of the recep-
tor. The limited quantities of tissue available from urogenital
ridges obtained at the appropriate embryonic stage has made
it difficult to purify or biochemically analyze the receptor.
Iodinated highly purified MIS binds specifically to A-431
cells (73) and to fetal rat lung fibroblasts (57); thus these two
cell types may offer a more abundant source of MIS receptor
than the minute amounts of mesenchymal tissue available
from the fetal undifferentiated urogenital ridge.
Several molecular approaches are being used to isolate
and clone the MIS receptor. Expression cloning using fluo-
resceinated or iodinated holo-MIS to screen urogenital ridge
libraries has been unsuccessful because of difficulties in
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maintaining the biological activity of labeled MIS (M. L.
Gustafson and P. K. Donahoe, unpublished data). Recent
data showing that the C-terminal fragment is the biologically
active moiety indicate that uncleaved holo-MIS is probably
a poor ligand for expression cloning. The requirement for
proteolytic cleavage of MIS to generate its active domain has
focused our attention on the C-terminal fragment as the
cognate ligand for the MIS receptor. Recent efforts to identify
the MIS receptor by expression cloning have concentrated
on screening with iodinated C terminus. Specific binding has
been difficult to detect and amplify, perhaps due to the low
abundance of the MIS receptor or decreased activity of
iodinated C terminus.
Parallel efforts to isolate the MIS receptor have focused on
on the likelihood that the MIS receptor is homologous to the
recently cloned activin (60) and TGF/32 receptors (61). These
closely related receptors have a single membrane-spanning
domain and are serine-threonine kinases. Degenerate oligo-
nucleotide primers complementary to homologous regions of
the activin and TGF/32 receptors have been designed for
polymerase chain reaction amplification of the MIS receptor
from an embryonic day 14 rat urogenital ridge cDNA library.
A candidate clone for the MIS receptor has been identified
and is currently being further characterized (W. W. He, M.
L. Gustafson, and P. K. Donahoe, unpublished data). This
putative MIS receptor has been localized to the mesenchymal
cells surrounding the Mullerian duct and to the developing
oocytes in preantral and antral follicles by in situ hybridiza-
tion. The mRNA is detected by Northern analysis in devel-
oping testes and mature ovaries, as well as in cell lines that
are growth-inhibited by MIS. Isolation of the MIS receptor
gene will enable studies to be designed that will increase the
understanding of the mechanism of action of MIS and delin-
eate other extra-Mullerian functions of MIS. In the clinical
setting, MIS receptor probes may be invaluable in preselect-
ing patients with tumors sensitive to MIS or its congeners.
IV. Physiological Functions of MIS
A. Mullerian duct regression
Mullerian duct regression occurs early in embryonic de-
velopment. Pre-Sertoli cells in the undifferentiated gonad
aggregate around the germ cells and form seminiferous cords
by day 13 postcoitus in the rat. By the afternoon of day 13,
before testosterone is detected in Leydig cells, MIS mRNA
and protein are detectable in the immature Sertoli cells (3,
20, 70). By day 15 postcoitus, hyaluronidase activity is in-
creased, and the extracellular matrix constituents, such as
fibronectin, start to disappear as mesenchyme surrounds the
duct, and dissolution of the duct begins (54, 71, 74). By day
16, the basement membrane has disappeared and hyaluron-
idase activity is lost. On day 17, the Mullerian duct is no
longer visible and only mesenchymal cells remain. When
15.5 day gestation Mullerian duct epithelium is separated
from the mesothelium and cultured separately with MIS,
both cell types survive, although [3H]thymidine incorpora-
tion is decreased in the mesothelial but not in the epithelial
cells (72). These data reveal that MIS exerts its effects on the
ductal epithelium via the surrounding mesenchyme. Human
male fetal genital tracts have signs of ductal regression that
are irreversible by 51 days postovulation (75). Coculture of
the urogenital ridge of female fetuses less than 25 mm in
crown-rump length with testicular tissue results in regression
of the Mullerian duct, while the ducts of fetuses greater than
30 mm in crown-rump length are no longer responsive to
MIS (3).
Picon (13) first developed an organ culture assay to mon-
iter MIS bioactivity in vitro, a crucial step in advancing the
study of this hormone. Fetal rat urogenital ridges were placed
in organ culture for 3 days, then examined histologically for
regression of the Mullerian duct. At 14.5 to 15.5 days post-
coitus, the Mullerian ducts of both male and female rat
fetuses are histologically similar and respond similarly in
culture. Urogenital ridges obtained from older female fetuses
have incomplete regression of the Mullerian duct when
cultured with MIS, while the Mullerian ducts of older male
fetuses involute in culture even in the absence of MIS. Thus,
the sensitivity of the Mullerian ducts to the inhibitory effects
of MIS depends primarily on the age of the urogenital ridge.
Biochemical and cellular changes characteristic of ductal
regression proceed irreversibly if exposure to MIS has oc-
curred before 15 days, even if MIS is subsequently removed
(3, 13, 76). Conversely, ducts that have not been exposed to
MIS by 15 days gestation no longer fully involute in response
to the hormone.
Picon's organ culture assay has been modified to establish
a graded bioassay in which 14.5 day female rat embryonic
urogenital ridges are incubated with the tissue fragment,
conditioned media, or biological fluid to be tested (Fig. 3)
(76). To facilitate, morphological comparison, testosterone is
added to the media at 10~9 M to enhance the effect of MIS
and stimulate growth of the Wolffian duct {77). After 72 h
incubation in humidified 5% CO2, the specimen is sectioned
and stained with hematoxylin and eosin. Regression of the
Mullerian duct is graded from 0 (no regression) to 5 (complete
regression) by at least two independent observers. The organ
culture bioassay requires 1.5-2 Mg/ml of recombinant holo-
MIS for full ductal regression. A similar assay has been
established with the mouse urogenital ridge (14). Because of
the differing sensitivity of the cephalic and caudal ends of
the urogenital ridge to MIS, Josso and colleagues (3) quanti-
tate ductal regression as "complete, near-complete, incom-
plete, and no regression" by assessing the extent (length) of
the regression. The organ culture assay of Mullerian duct
regression remains the most specific assay for MIS activity,
against which all others are compared. An understanding of
the regression of the Mullerian duct under these experimental
conditions helps to clarify the conditions under which the
Mullerian duct regresses in intersex abnormalities or fails to
undergo regression in the persistent Mullerian duct syn-
drome.
Persistent Mullerian duct syndrome (PMDS) is a hetero-
geneous disorder, with evidence for both end-organ unre-
sponsiveness to MIS despite normal production of the hor-
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 13 August 2014. at 11:15 For personal use only. No other uses without permission. . All rights reserved.
158 LEE AND DONAHOE Vol. 14, No. 2
FIG. 3. The Mullerian duct organ cul-
ture assay for MIS. A schematic of the
organ culture bioassay is shown above
the histological sections of the urogenital
ridge. Female Mullerian ducts are incu-
bated on agar-coated stainless steel grids
for 72 h at 37 C, then fixed, sectioned,
and stained. Regression of the Mullerian
duct (M) is graded from 0 (no regression)
to 5 (full regression) and can be con-
trasted with the testosterone-stimulated
Wolffian duct (W). [Adapted with per-
mission from Donahoe et ai: J Surg Res
23:141-148,1977 (76).]
o. . .. 14 day female
S t e e l 9 n d mullerian duct Agar
Medium + MIS
D. Grade 3 E. Grade 4 F. Grade 5
mone and deficiency of the bioactive hormone. A PMDS dog
model that is carried as an autosomal recessive trait appears
to result from peripheral resistance (receptor defect) rather
than insufficient production of MIS (78, 78a). The homozy-
gous affected dogs and nonaffected dogs produce equivalent
amounts of MIS (78, 78a) that are bioactive in the rat uro-
genital ridge organ culture assay (78). The disorder in humans
appears to be heterogeneous in etiology as patients may have
either normal or absent serum MIS concentrations (79, 80).
Testicular biopsies of five patients with PMDS revealed the
presence of MIS mRNA in all of the specimens, although
only two had bioactive MIS (81). The three patients who
lacked bioactive or immunoreactive MIS were siblings who
were subsequently found to have point mutations in the fifth
exon of the MIS gene, which prematurely terminated trans-
lation, resulting in an unstable truncated protein (82). Addi-
tional patients with absent or bioinactive MIS are being
studied for other mutations of the MIS gene. Identification
of the MIS receptor gene will allow similar molecular analysis
of PMDS patients with presumed receptor defects.
B. Germ cell maturation and gonadal morphogenesis
In addition to its well-defined role in male sexual differ-
entiation, the ontogeny and function of MIS in the ovary
have also been examined (2, 8, 9). MIS has been detected in
ovaries and follicular fluid of many species and is synthesized
by the granulosa cells of the ovary. Bioactive MIS is first
detected in rat ovaries 3 days after birth, when the rat oocyte
becomes arrested in the dictyate or diffuse diplotene stage
(20, 70). In contrast to the generalized Sertoli cell pattern
seen in the testis, MIS clearly localizes to granulosa cells in
preantral and antral follicles but not to atretic or primordial
follicles, or to the corpus luteum (Fig. 4) (83). In the cycling
adult ovary, the same cells stain in preantral, antral, and
preovulatory follicles throughout estrus, metestrus, diestrus,
and early proestrus. In late proestrus, as progesterone levels
rise just before ovulation when the oocyte resumes meiotic
division, the staining in the preovulatory follicles wanes. In
situ hybridization shows that MIS mRNA is abundant in
granulosa cells surrounding preantral and small antral folli-
cles and most prominent in cells proximal to the follicular
lumen (70).
Observations of abnormalities in sexual differentiation and
development caused by inappropriate expression of MIS led
to hypotheses about other functions of MIS in the reproduc-
tive system. Premature exposure of the female fetus to MIS
during early embryogenesis causes agenesis of the Mullerian
structures and an "endocrine sex-reversal" of the ovaries (22,
84, 85). Immature ovaries cultured with MIS have decreased
aromatase activity, resulting in increased testosterone syn-
thesis (85). The ability of MIS to change the sex steroid
secretion of immature ovaries may explain the virilization
and seminiferous tubule formation in ovaries of freemartin
calves that are exposed to MIS in utero and is consistent with
the hypothesis that the appropriate expression of MIS is
important in gonadal differentiation. The absence of MIS is
critical for normal ovarian steroidogenesis, and the presence
of MIS in the immature testes may enhance testosterone
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FIG. 4. MIS protein and mRNA in the
rat ovary. Immunohistochemical stain-
ing of the 21 day (A) and 27 day (B)
ovary shows more intense immunoreac-
tivity of the inner granulosa cells and
cumulus cells of the preantral (PAF) and
smaller antral (AF) follicles than that of
larger antral follicles (S and T). (x200).
Lightfield (C) and darkfield (D) in situ
hybridization of the 21 day ovary dem-
onstrates MIS mRNA in the granulosa
cells surrounding preantral (PAF) and
antral (AF) follicles but not in atretic
follicles (ATR). [Adapted with permis-
sion from Ueno et al.: Endocrinology
131:854-862,1989 (70) and Hirobe etai:
Endocrinology 124:1000-1006,1992 (83).
®The Endocrine Society.]
c
synthesis and decrease estrogen production. Another bioas-
say for MIS has been developed utilizing this effect of MIS
(85). Fetal ovaries are incubated with MIS and [3H]andro-
stenedione for 3 days. The aromatase activity of the gonads
is quantitated by measuring the amount of [3H]H2O gener-
ated and correlates inversely with the log concentration of
MIS in the culture.
MIS continues to be produced in the testes throughout
gestation while the germ cells are entering a state of meiotic
and mitotic arrest. Jost first proposed that a Sertoli cell factor
such as MIS might inhibit Sertoli cell mitosis and prevent
germ cells from entering meiotic prophase (86). The function
that MIS subserves in adult testes is still not fully understood,
but studies in sex-reversed B6.YDOM mice (21) and reports of
an oocyte meiosis inhibitory effect of MIS (58, 87) are in
agreement with a role for MIS in the control of germ cell
maturation. Sex-reversed B6.YDOM male mice develop ovo-
testes with poorly organized testis chords and abnormal germ
cell differentiation (21). The centrally located germ cells are
arrested at the prespermatogonial prophase and are sur-
rounded by MIS positive cells, in contrast to the polar, more
mature germ cells in meiotic prophase that are surrounded
by MIS negative cells. The pathogenesis of the sex reversal
appears to be the delayed onset and progression of testicular
differentiation with a concomitant delay in MIS expression.
Although these data demonstrate the striking physical prox-
imity of MIS with immature germ cells, a causative role for
MIS in the regulation of germ cell maturation is not proven.
Purified bovine MIS, in a concentration-dependent, re-
versible, and cAMP-independent manner has been shown
to inhibit resumption of meiosis in both denuded and cu-
mulus-enclosed rat oocytes, using germinal vesicle break-
down as a measure of meiotic division (87). Purified rhMIS
has similar effects in the presence of low concentrations of
NP40, a stabilizing detergent, which may reduce the aggre-
gation that occurs when MIS is highly concentrated by
affinity chromatography. It has been argued that the inhibi-
tion of oocyte meiosis is mediated by NP-40 rather than by
MIS (88); however, at the concentration used, NP-40 alone
affects neither regression of the Mullerian duct nor inhibition
of oocyte meiosis, while at 100-fold higher concentrations it
has expected toxicity (58). Furthermore, the reversal of the
inhibitory effect of rhMIS on oocyte meiosis by anti-MIS
antibody and EGF provides additional evidence of its speci-
ficity (58). MIS, therefore, may have a functional role in the
control of oocyte meiosis, although the mechanism for this
action remains to be elucidated. The ability of MIS to inhibit
either cumulus enclosed or denuded oocytes indicates that
its action on the germ cell is direct, in contrast to oocyte
maturation inhibitor, which acts via cumulus cell-induced
cAMP (89). The interactions of these two inhibitors of oocyte
meiosis deserve further investigation. The finding that MIS
may control germ cell maturation in both the male and female
raises possibilities for its future development as a model for
contraception. The use of MIS as a contraceptive agent would
have the advantage of minimal toxicity and side effects based
on the lack of systemic toxicity found in patients with MIS-
producing ovarian tumors who have extremely elevated
serum MIS levels (as discussed below).
Other roles postulated for MIS were based on the pheno-
types of transgenic mice that produce supraphysiological
levels of MIS (22). The female mice have virilized external
genitalia and blind-ending vaginas with no uteri or oviducts.
Their gonads have cord-like structures resembling seminif-
erous tubules and lack germ cells. Conversely, the male
transgenic mice that have the highest expression of MIS are
infertile with feminized external genitalia, under-developed
Wolffian structures, and germ-cell deficient, undescended
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testes. Male mice with lower levels of MIS are fertile with
normal sexual development. These experiments illustrate the
critical role that MIS may have in gonadal morphogenesis,
which may then secondarily affect differentiation of the
external genitalia. Experiments to silence the MIS gene will
be helpful in delineating the critical role of MIS in normal
gonadal and sexual differentiation.
C. Lung maturation
In humans, newborn respiratory distress syndrome sec-
ondary to pulmonary immaturity from surfactant deficiency
occurs more frequently in males than females (90). Andro-
gens have been shown to inhibit the synthesis of phospha-
tidylcholine, a major component of surfactant, by immature
pulmonary fibroblasts (90). Because testosterone is synergis-
tic with MIS in the organ culture assay (77), and MIS is
present at high serum concentrations in the fetus during the
period of late lung maturation when testosterone levels are
falling, the effect of MIS on phosphatidylcholine accumula-
tion was examined (25). Lung fragments from 17.5 day
gestation female fetuses were incubated with fetal testes or
ovaries, or with nanomolar concentrations of bovine MIS or
picomolar concentrations of rhMIS. Both testicular fragments
and purified MIS preparations suppress the accumulation of
disaturated phosphatidylcholine compared to lungs cultured
with ovaries or buffer. Similar experiments were repeated in
vivo, by intrauterine injection of nanomolar concentrations
of rhMIS in the dorsal subcutaneous tissue of 19 day gesta-
tion fetuses (26). Lungs were harvested from the treated
embryos 48 and 72 h after the injection, then assayed for
disaturated phosphatidylcholine. As compared to buffer-
injected controls, the lungs of female fetuses treated with
rhMIS have a marked diminution of phosphatidylcholine.
As an inhibitor of surfactant accumulation in the male fetus,
MIS is being further investigated as a potential culprit in the
increased incidence of neonatal respiratory distress syndrome
in males.
Confocal microscopy shows binding of MIS to fetal lung
sections; first in punctate patches on the cell surface and
perinuclear area, later in the cytoplasm and nucleus (91). The
mechanism by which this large, initially membrane bound
glycoprotein localizes to the nucleus remains to be elucidated
but presumably occurs via a specific MIS receptor-mediated
event that leads to nuclear accumulation. The finding of MIS
responsivity and binding in the fetal lung provides an alter-
native, more easily collected source of material for the puri-
fication, characterization, and cloning of the MIS receptor.
D. Testicular descent
A triphasic model for descent of the testes has been
proposed in which the first stage is the nephric displacement
of the gonad early in embryogenesis, which occurs in both
males and females. The second stage is the transabdominal
movement of the testes as a result of rapid gubernacular
growth, and the third stage is movement through the inguinal
canal (24). The second stage is postulated to be under MIS
control (8, 24), while the third stage is thought to be mediated
by androgens. Clinical observations provided clues to the
function of MIS in testicular descent. In the androgen resist-
ance syndrome, in which androgen action is lacking but MIS
action is normal, the testes have descended to the inguinal
ring in the majority of affected patients and animals (92, 93).
Conversely, in the persistent Mullerian duct syndrome, in
which MIS action is lacking but androgen action is normal,
the testes usually fail to descend and are abdominal in
position, unless herniation occurs (81,94). Interestingly, dogs
with the persistent Mullerian duct syndrome, who have been
shown to produce bioactive MIS, may have either scrotal or
abdominal testes (78). The cryptorchidism of patients with
the persistent Mullerian duct syndrome has also been attrib-
uted to mechanical restraint from the retained ductal struc-
tures, which limits movement of the testes, rather than from
a direct effect of MIS (95). Male offspring of rabbits immu-
nized against MIS during early gestation, before differentia-
tion of the genital tracts, have persistence of the Mullerian
ducts but normal testicular descent (96). These experiments,
however, did not conclusively exclude a role for MIS in
testicular descent because the timing of the immunization
was selected to affect Mullerian development and may not
have been optimal for inhibition of testicular descent.
The finding of lower MIS bioactivity in testicular biopsies
of infants with cryptorchidism compared to age-matched
controls support the hypothesis for a role of MIS in testicular
descent (23). Patients with undescended testes have also
been reported to have lower serum MIS concentrations than
normals at 8 to 12 months, 2 to 3 yr, and 6-7 yr of age (97).
Although these observations are consistent with a role for
MIS in testicular descent, many cases of cryptorchidism are
secondary to an abnormality in the transinguinal phase of
testicular descent; therefore the lower MIS values may reflect
degeneration or dysgenesis of the abdominal testes. Although
the gubernaculum is thought to be the target organ for the
MIS-mediated phase of testicular descent (24), its morpho-
genic movements are not well understood. Purified bovine
MIS did not stimulate DNA synthesis in isolated guberna-
cular cells (98). The effects of MIS on the gubernaculum may
be indirect or may require intact tissue rather than isolated
cells. Examination of MIS receptor expression in the guber-
naculum will help further define this proposed function of
MIS.
E. Growth inhibition of transformed cells
The role of MIS as a fetal growth inhibitor raised the
theoretical consideration that MIS might continue to act
postnatally on tissues of Mullerian duct origin to suppress
malignant transformation. It was further postulated that MIS
might be used as a therapeutic tumor regressor to restore
growth control of neoplastic cells (28). The mechanisms
responsible for the process of Mullerian duct regression might
provide a model for the development of targeted biological
modifiers with reduced toxicity and increased specificity.
Tumors from reproductive tract structures derived from the
Mullerian duct were first tested as potential MIS targets.
Ovarian epithelial carcinomas were studied because they
histologically resemble tissues derived from the embryonic
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Mullerian ducts and arise from the surface epithelium of the
ovary, a derivative of the coelomic epithelium that originally
invaginated to form the Mullerian ducts. These tumors rep-
resent 95% of ovarian carcinomas in the human and occur
predominantly in the postmenopausal ovary after MIS pro-
duction ceases. HOC-21, a human ovarian carcinoma line,
was inhibited by partially purified bovine MIS in monolayer
microcytotoxicity assays (28), colony inhibition (99), and as
transplants in nude mice (100). Bovine MIS also inhibited
colony growth of a number of primary ovarian, endometrial,
and tubal carcinomas (4, 101).
The method of purification of MIS may affect its activation
and, therefore, has significant influence on its growth-inhib-
itory properties. Bovine MIS that was first lentil-lectin ex-
tracted, then purified by immunoaffinity chromatography
was not cytotoxic to an endometrial cell line (102). Nano-
molar concentrations of highly purified rhMIS inhibited only
three of 13 primary ovarian cancer explants and one small
cell carcinoma of the lung in soft agar colony-forming assays
(49). The rhMIS was purified by immunoaffinity chromatog-
raphy, then eluted with chaotropic salts, and was shown to
be 95% pure by polyacrylamide gel electrophoresis, N-ter-
minal amino acid sequencing, and amino acid composition
analysis. Polyacrylamide gel electrophoresis analysis, how-
ever, indicated that little cleavage had occurred. Furthermore,
in contrast to immunoaffinity- purified rhMIS, rhMIS puri-
fied by ion exchange and carbohydrate affinity chromatog-
raphy caused significant growth inhibition of the human
endometrial cell line HTB-111 implanted under the subrenal
capsules of irradiated CD-I mice (A. K. Goodman and P. K.
Donahoe, unpublished data).
The purification of MIS by immunoaffinity chromatogra-
phy was subsequently improved to include a simple salt
elution step before acid elution of MIS (11). This preparation,
freed of a co-eluting contaminant which itself stimulated
growth, was found to be effective in inhibiting a variety of
gynecological tumors in vivo and in vitro (27) as well as a
human ocular melanoma cell line (30). When holo-MIS was
cleaved with plasmin and N- and C-terminal fragments
separated by size chromatography, the bioactive C-terminal
fragment also inhibited A-431 cells in an in vitro antiprolif-
erative assay (29). Thus, activation of MIS by proteolytic
cleavage is essential for its growth-inhibitory properties. The
antiproliferative activity of the C-terminal fragment is cur-
rently being examined in animal models. One limitation of
using the active C-terminal domain in vivo rather than holo-
MIS is its rapid degradation. The N-terminal fragment may
help prolong the half-life of MIS in serum, so the optimal
system may require that the cleavage and activation of MIS
occur at the targeted tumor. Efforts are underway to identify
the proteolytic enzyme endogenous to the urogenital ridge
that cleaves holo-MIS, and to develop the most specific
antiproliferative ligand for therapeutic use.
V. Clinical Applications for Serum MIS Measurements
A. Evaluation of intersex disorders
MIS can now be detected in serum of normal infants,
children, and adults in the nanogram per ml range, with a
sensitivity as low as 0.5 to 1.0 ng/ml (Fig. 5) (14-16). Serum
concentrations of MIS in young males are 10-70 ng/ml at
birth, then increase slightly during the first year. During
childhood, MIS gradually decreases to the basal levels (2-5
ng/ml) found from adolescence through adulthood (15). In
contrast to the high levels in males during infancy and early
childhood, MIS is not measurable in females for several years
after birth and is first detectable during the second decade.
Serum MIS concentrations during the reproductive years are
comparable to those seen in the adult male. Similar levels
are found in adult ovarian follicular fluid harvested during
procedures for in vitro fertilization (C. Richards, D. T.
MacLaughlin, and P. K. Donahoe, unpublished data).
The sexually dimorphic secretion of MIS before puberty
makes it a sensitive and specific marker for testicular tissue.
Measurement of serum MIS may be a valuable adjunct in
FIG. 5. Graph of serum MIS concentra-
tions in normal male and female controls
from infancy to adulthood as measured
by the MIS enzyme-linked immunosor-
bent assay. [Reprinted with permission
from Hudson et al.: J Clin Endocrinol
Metab 70:16-22, 1990 (15). ©The Endo-
crine Society.]
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the evaluation of gonadal disorders, particularly during the
neonatal and prepubertal physiological nadir of testosterone
secretion when male and female testosterone levels are in-
distinguishable. Serum MIS concentrations have been used
diagnostically to confirm the presence of testicular tissue in
patients with anorchia and/or intersex anomalies (79, 80).
MIS determination has also been useful for ensuring the
complete removal of testicular tissue in the postoperative
management of patients undergoing gonadectomies because
of female gender assignment or potential for malignant de-
generation.
B. Tumor marker
Serum MIS measurement has proven to be useful in the
evaluation of selected patients with gonadal tumors. One
female patient with an MIS-secreting sex cord tumor with
annular tubules had serum MIS values as high as 3.2 Mg/ml
(500-1000 times normal), which decreased markedly after
surgical resection (103). Her prolonged clinical course was
marked by multiple tumor recurrences that correlated with
elevations in MIS levels. After each resection of bulk tumor,
her MIS levels decreased correspondingly. Several other
patients with granulosa cell tumors have also had elevated
serum MIS values that decreased after surgery (79, 103).
Therefore, in patients with MIS-secreting granulosa or sex
cord tumors, MIS measurements may serve as a predictive
marker of persistent or recurrent disease.
VI. Conclusion
MIS is a growth-inhibitory glycoprotein synthesized by
Sertoli and granulosa cells that is related to the TGF/3 super-
family of growth and differentiating agents. The sexually
dimorphic expression of MIS at the appropriate time is
essential for normal gonadal morphogenesis and sexual dif-
ferentiation. Although MIS was originally defined for its role
in the regression of the Mullerian ducts during normal male
sexual differentiation, a large number of extra-Mullerian
functions have subsequently been described. These include
the regulation of germ cell maturation and gonadal morpho-
genesis, control of testicular descent, suppression of tumor
growth, and inhibition of lung maturation. Consequently,
dysregulated or abnormal expression of MIS results in dis-
ruption of both normal gonadal maturation and reproductive
tract development. Much progress has been made in the
understanding of the biology of MIS since it was first de-
scribed almost 50 yr ago. Further elucidation of the regulation
and mechanism of action of this potent fetal growth inhibitor
will provide insights concerning the control of growth and
differentiation.
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